| From: |
|
Alison Bunce - Medicines and Healthcare Products Regulatory Agency
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Trusts (England) - Medical Director
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
|
|
|
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Chief Executive
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
DRUG ALERT CLASS 4, FOR INFORMATION, CADIASUN PHARMA GMBH, CASPOFUNGIN 70MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
|
| Broadcast content: |
|
We have been informed that there are errors in the text on both the SPC and Patient Information Leaflet for this product.Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA websitehttps://www.gov.uk/drug-device-alerts We understand that this product is used in hospitals and is unlikely to be used in General Practice or Community Pharmacy. Please do not send this communication to Community Pharmacists or to GPs unless they are known to use the product outside the hospital setting.
|